FATE
Price
$1.03
Change
-$0.01 (-0.96%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
119.94M
58 days until earnings call
MGNX
Price
$1.73
Change
-$0.04 (-2.26%)
Updated
Sep 2, 04:59 PM (EDT)
Capitalization
111.87M
70 days until earnings call
Interact to see
Advertisement

FATE vs MGNX

Header iconFATE vs MGNX Comparison
Open Charts FATE vs MGNXBanner chart's image
Fate Therapeutics
Price$1.03
Change-$0.01 (-0.96%)
Volume$5.66K
Capitalization119.94M
MacroGenics
Price$1.73
Change-$0.04 (-2.26%)
Volume$5.49K
Capitalization111.87M
FATE vs MGNX Comparison Chart in %
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. MGNX commentary
Sep 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and MGNX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 03, 2025
Stock price -- (FATE: $1.04 vs. MGNX: $1.77)
Brand notoriety: FATE and MGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 59% vs. MGNX: 97%
Market capitalization -- FATE: $119.94M vs. MGNX: $111.87M
FATE [@Biotechnology] is valued at $119.94M. MGNX’s [@Biotechnology] market capitalization is $111.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileMGNX’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • MGNX’s FA Score: 0 green, 5 red.
According to our system of comparison, FATE is a better buy in the long-term than MGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 5 TA indicator(s) are bullish while MGNX’s TA Score has 3 bullish TA indicator(s).

  • FATE’s TA Score: 5 bullish, 3 bearish.
  • MGNX’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than MGNX.

Price Growth

FATE (@Biotechnology) experienced а -9.57% price change this week, while MGNX (@Biotechnology) price change was +4.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.83%. For the same industry, the average monthly price growth was +22.37%, and the average quarterly price growth was +32.94%.

Reported Earning Dates

FATE is expected to report earnings on Oct 30, 2025.

MGNX is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+6.83% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($120M) has a higher market cap than MGNX($112M). FATE YTD gains are higher at: -36.970 vs. MGNX (-45.538). MGNX has higher annual earnings (EBITDA): -26.91M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. MGNX (176M). MGNX has less debt than FATE: MGNX (37.2M) vs FATE (81.3M). MGNX has higher revenues than FATE: MGNX (164M) vs FATE (8.47M).
FATEMGNXFATE / MGNX
Capitalization120M112M107%
EBITDA-161.6M-26.91M600%
Gain YTD-36.970-45.53881%
P/E RatioN/AN/A-
Revenue8.47M164M5%
Total Cash223M176M127%
Total Debt81.3M37.2M219%
FUNDAMENTALS RATINGS
FATE vs MGNX: Fundamental Ratings
FATE
MGNX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
14
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
8655
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is somewhat better than the same rating for MGNX (79). This means that FATE’s stock grew somewhat faster than MGNX’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MGNX (100). This means that FATE’s stock grew similarly to MGNX’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as MGNX (98). This means that FATE’s stock grew similarly to MGNX’s over the last 12 months.

MGNX's Price Growth Rating (55) in the Biotechnology industry is in the same range as FATE (86). This means that MGNX’s stock grew similarly to FATE’s over the last 12 months.

MGNX's P/E Growth Rating (95) in the Biotechnology industry is in the same range as FATE (100). This means that MGNX’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEMGNX
RSI
ODDS (%)
Bullish Trend 5 days ago
89%
N/A
Stochastic
ODDS (%)
Bullish Trend 5 days ago
79%
Bearish Trend 5 days ago
90%
Momentum
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
78%
MACD
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 5 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
85%
Advances
ODDS (%)
Bullish Trend 7 days ago
86%
N/A
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
N/A
Bearish Trend 5 days ago
87%
Aroon
ODDS (%)
Bullish Trend 5 days ago
80%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TPICQ0.04N/A
+4.57%
TPI Composites, Inc.
ITFS2.150.02
+0.94%
ITAFOS INC.
RUBSF33.31N/A
N/A
RUBIS
HALMY89.00-0.52
-0.58%
Halma PLC
LQWDF1.31-0.03
-2.25%
LQWD TECHNOLOGIES CORP.

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with ALLO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then ALLO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
-3.70%
ALLO - FATE
53%
Loosely correlated
-4.24%
RXRX - FATE
53%
Loosely correlated
-3.39%
CRBU - FATE
52%
Loosely correlated
-3.61%
MGNX - FATE
52%
Loosely correlated
+4.12%
NTLA - FATE
50%
Loosely correlated
-2.11%
More